Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing date is March 11, 2026, covering a share purchase executed on March 10, 2026. The transaction was conducted by BNP Paribas SA acting as a broker under a non-discretionary agreement announced on February 17, 2026.
Key Financial Metrics
The filing details a specific share repurchase event rather than comprehensive financial statements. Key metrics for the transaction include:
- Shares Purchased: 505,000 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 2,052.00 GBp; highest price paid was 2,082.00 GBp.
- Average Price: Volume-weighted average price paid was 2,066.69 GBp.
- Treasury Holdings: Following this purchase, GSK holds 248,068,094 ordinary shares in treasury.
- Shares in Issue: 4,068,100,728 ordinary shares (excluding treasury shares).
- Voting Rights: Treasury shares represent 6.10% of total voting rights.
Revenue, profit, cash flow, margins, and debt figures are not provided in this filing.
Material Changes
Since the commencement of the buyback agreement on February 17, 2026, the company has purchased a total of 8,177,000 ordinary shares. The March 10 transaction increased the treasury share count, reducing the number of shares in issue and increasing the percentage of voting rights held in treasury to 6.10%.
Guidance, Outlook, and Risks
The filing confirms the purchase is part of the company's existing buyback programme. No new financial guidance or operational outlook is provided. The document includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially due to risks described in the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2025.
Investor Verification Checklist
- Verify the total cumulative buyback volume since February 17, 2026 (stated as 8,177,000 shares).
- Confirm the updated treasury share count of 248,068,094 shares.
- Review the 6.10% voting rights held in treasury against regulatory disclosure thresholds.
- Check the remaining authorization under the existing buyback programme to assess future repurchase capacity.